Adocia SA (ADOCY)
- Business Wire
ADOCIA Announces the Release of Its Universal Registration Document for the Year 2023
LYON, France, April 29, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today the filing of its 2023 Universal Registration Document with the "Autorité des marchés financiers" (AMF - the French financial markets regulator) on April 29, 2024.
- Business Wire
ADOCIA Announces Full Year 2023 Financial Results and Provides a Corporate and Financial Update
LYON, France, April 24, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces today its annual financial results as of December 31, 2023. The consolidated financial statements contained herein were approved by Adocia’s board of directors on April 23, 2024. These statements will be presented to share
- Business Wire
Number of Shares and Voting Rights of ADOCIA as of March 31st, 2024
LYON, France, April 12, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions f
